My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Arrowhead Pharmaceuticals, Inc. - Common Stock (NQ:ARWR)

40.45 +2.36 (+6.20%)

Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Arrowhead Pharmaceuticals, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Where Arrowhead Pharmaceuticals Stands With Analysts ↗

May 24, 2022

Within the last quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 11, 2022 ↗

May 11, 2022

Upgrades

Via Benzinga

Arrowhead Pharmaceuticals: Q2 Earnings Insights ↗

May 10, 2022

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q2 earnings results on Tuesday, May 10, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Arrowhead Pharmaceuticals Reports Fiscal 2022 Second Quarter Results

May 10, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves ↗

May 10, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Arrowhead Breaks Ground on New Manufacturing Facility with Wisconsin Governor Tony Evers and Announces Receipt of Incentives

May 09, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals Appoints Victoria Vakiener to Board of Directors

May 02, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming May 2022 Conferences

May 02, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Week In Review: I-Mab Files For Hong Kong SPAC IPO To Acquire Life Science Company ↗

April 30, 2022

I-Mab and one of its investors, VMS, have filed for a Hong Kong IPO of a SPAC that will raise funds to acquire a life science company. Also, RVAC Medicines completed a Series B funding that brings...

Via Talk Markets

Arrowhead Pharmaceuticals to Host Pulmonary R&D Day

April 27, 2022

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 2 GATEWAY Study of Investigational ARO-ANG3 for Treatment of Homozygous Familial Hypercholesterolemia

April 26, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals and Vivo Capital Launch Joint Venture Aimed at Greater China Market

April 25, 2022

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

The Week Ahead In Biotech (April 24-April 30): Bristol-Myers Squibb, Supernus, Hutchmed, Axsome, Coherus FDA Decisions, Big Pharma Earnings, IPOs And More ↗

April 24, 2022

Biotech stocks extended their loses in the week ending April 22. The sector took cues from the broader market, which reacted to the lackluster start of the first-quarter reporting season and lingering...

Via Benzinga

Arrowhead Pharmaceuticals to Webcast Fiscal 2022 Second Quarter Results

April 20, 2022

From Arrowhead Pharmaceuticals Inc.

Via Business Wire

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

April 06, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Pharmaceuticals to Participate in Upcoming April 2022 Conferences

April 01, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MUC5AC for Treatment of Muco-Obstructive Lung Diseases

March 24, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-RAGE for Treatment of Asthma

March 15, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Completes Enrollment in Phase 2b ARCHES-2 Study of Investigational ARO-ANG3 for Patients with Mixed Dyslipidemia

February 24, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

10 Health Care Stocks With Whale Alerts In Today's Session ↗

February 23, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation

February 21, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Bronstein, Gewirtz & Grossman, LLC Notifies Shareholders of Arrowhead Pharmaceuticals, Inc. (ARWR) Investigation

February 18, 2022

From Bronstein, Gewirtz & Grossman, LLC

Via Business Wire

Arrowhead Pharmaceuticals Initiates Phase 1/2 Study of ARO-C3 for Treatment of Complement Mediated Diseases

February 18, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

Arrowhead Presents New Clinical Data on ARO-HIF2 at ASCO GU 2022

February 17, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Best Russell 2000 Stocks to Buy Before they Rebound ↗

February 15, 2022

Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.

Via InvestorPlace

Arrowhead Pharmaceuticals's Return On Capital Employed Insights ↗

February 03, 2022

According to data from Benzinga Pro, during Q1, Arrowhead Pharmaceuticals's (NASDAQ:ARWR) reported sales totaled $27.44 million. Despite a 0.79% increase in earnings, the company posted a loss of...

Via Benzinga

The Daily Biotech Pulse: Big Pharma Earnings Prove Lackluster, Mersana Inks $1B ADC R&D Deal, Syros Gets Orphan Drug Designation ↗

February 03, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Recap: Arrowhead Pharmaceuticals Q1 Earnings ↗

February 03, 2022

Arrowhead Pharmaceuticals (NASDAQ:ARWR) reported its Q1 earnings results on Wednesday, February 2, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

Via Benzinga

Arrowhead Pharmaceuticals Reports Fiscal 2022 First Quarter Results

February 02, 2022

From Arrowhead Pharmaceuticals, Inc.

Via Business Wire

The Daily Biotech Pulse: LogicBio Genome Editing Therapy Study Placed On Clinical Hold, Gilead Q4 Disappoints On Slowing Veklury Sales ↗

February 02, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.